Trial Profile
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; Vusolimogene oderparepvec (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CERPASS
- Sponsors Replimune
- 05 Dec 2023 According to a Replimune media release, trial will continue as planned to assess DOR, progression free survival (PFS) and overall survival (OS) with greater maturity.
- 05 Dec 2023 Primary endpoint (Complete Response Rate (CRR) according to blinded independent review) has not been met, according to a Replimune media release.
- 05 Dec 2023 Primary endpoint (Objective Response Rate (ORR) according to blinded independent review) has not been met, according to a Replimune media release.